



P0141
HBV 1000 copies/mL
genotype reference panel

RUO

REF

P0141



The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance



Table of contents

Intended Use..... 3

Summary and Explanation 3

Instructions for Use 3

Key to Symbols Used 3

Materials Provided 4

Materials not provided..... 4

Composition of HBV genotype reference panel 4

Calibration of secondary HBV standards and traceability to WHO International Standard 5

Statistical evaluation of quantitative results 6

Precautions..... 6

Storage Instructions..... 6

Limitations..... 6

References..... 7

www.h-h-c.com

Intended Use

The P0141 Hepatitis B virus (HBV) 1000 copies/mL genotype reference panel enables IVD manufacturers, clinical virology or blood screening laboratories to assess the genotype detection efficiency of nucleic acid amplification test (NAT) methods for the qualitative and quantitative detection of HBV-DNA in plasma samples. This reference panel can be used with amplification methods, including real time PCR and TMA assays and is useful for development and validation of NAT systems. This product is for research use only.

Summary and Explanation

The P0141 HBV 1000 copies/mL genotype reference panel is designed for evaluating the accuracy of quantitative NAT methods (or analytical sensitivity of qualitative NAT methods) in detecting different HBV genotypes. In total 21 different secondary HBV genotype standards that have been extensively characterized in different NAT methods^{1,2,3} and 4 negative controls are included in the reference panel (see Table with panel composition below). The range of genotypes covers most of the subgenotypes that are prevalent around the world. The concentration in all panel members is standardized to 1000 copies/mL (approximately 190 IU/mL) as cross calibrated in multiple parallel Siemens Versant bDNA 3.0 assays⁴. This level is far enough above the quantification limit of sensitive viral load assays to obtain consistent quantitative results. The reference panel helps ensure that NAT methods for HBV-DNA detection are properly validated. The HBV standards have been diluted in a pool of plasma units that tested negative for the regular viral markers in individual donation NAT and serology screening assays. The viral concentrations in the plasma pools are ensured by gravimetrically recorded dilutions from calibrated viral stock solutions stored at -30°C.

Instructions for Use

Thaw the panel members quickly in a water bath at 37°C to avoid formation of cryoprecipitates, mix gently during thawing until ice clot has disappeared. Immediately after thawing, vortex briefly, and give a short spin before releasing screw cap from the vials. The panel members should be handled and tested in a manner identical to that required for clinical specimens run in the test method being evaluated. Follow the manufacturers or laboratory instructions and recommendations for the handling and testing of clinical specimens.

Key to Symbols Used



Date of manufacturing



Manufacturer



Lot number



Catalogue number



Research Use Only



Store at -30°C



Biological substance category B



Expiry date



Contents



Caution



Read instructions for use

Materials Provided

25 x 4.3 mL plasma samples filled off in polypropylene tubes with screw cap divided in 3 parts

Materials not provided

Pipettes or pipetting devices to be used for IVD test systems

Composition of HBV genotype reference panel

| Sample nr. | Secondary Standard ^{1,2,3} | HBsAg serotype | Origin | copies/mL (95% CI) |
|------------|-------------------------------------|----------------|--------------|--------------------|
| 1 | Sanquin-VQC HBV-DNA genotype A1 | adw2 | Netherlands | 1000 (982-1023) |
| 2 | BQC HBV-DNA genotype B1 | ayw1 | Indonesia | 1000 (835-1201) |
| 3 | BQC HBV-DNA genotype C1 | adr | USA | 1000 (846-1181) |
| 4 | BQC HBV-DNA genotype D1 | ayw2 | USA | 1000 (852-1173) |
| 5 | BQC HBV-DNA genotype E1 | ayw3 | USA | 1000 (904-1108) |
| 6 | BQC HBV-DNA genotype F1 | adw4 | USA | 1000 (642-1559) |
| 7 | BQC HBV-DNA genotype G1 | adw2 | USA | 1000 (831-1203) |
| 8 | Eurohep HBV-DNA genotype A21,2 | adw2 | Germany | 1000 (599-1667) |
| 9 | Eurohep HBV-DNA genotype D1,2 | ayw2/3 | Germany | 1000 (803-1253) |
| 10 | WHO HBV-DNA genotype A13 | adw2 | South Africa | 1000 (632-1583) |
| 11 | WHO HBV-DNA genotype A13 | adw2 | Brasilia | 1000 (531-1885) |
| 12 | WHO HBV-DNA genotype A23 | adw2 | Germany | 1000 (833-1200) |
| 13 | WHO HBV-DNA genotype B13 | adw2 | Japan | 1000 (642-1556) |
| 14 | WHO HBV-DNA genotype B23 | adw2 | Japan | 1000 (673-1485) |
| 15 | WHO HBV-DNA genotype C23 | adr | Japan | 1000 (678-1453) |
| 16 | WHO HBV-DNA genotype C23 | adr | Japan | 1000 (728-1373) |
| 17 | WHO HBV-DNA genotype C23 | adr | Russia | 1000 (734-1362) |
| 18 | WHO HBV-DNA genotype D13 | ayw2 | Germany | 1000 (634-1573) |
| 19 | WHO HBV-DNA genotype D33 | ayw2 | South Africa | 1000 (802-1245) |
| 20 | WHO HBV-DNA genotype D13 | ayw3 | Iran | 1000 (657-1524) |
| 21 | WHO HBV-DNA genotype E3 | ayw4 | West Africa | 1000 (794-1258) |
| 22 | Negative human plasma | | | |
| 23 | Negative human plasma | | | |
| 24 | Negative human plasma | | | |
| 25 | Negative human plasma | | | |

Statistical evaluation of quantitative results

The samples in the P0141 HBV 1000 cps/mL genotype reference panel have been carefully formulated to mimic human plasma specimens containing 1000 copies/ml of HBV-DNA according to the Siemens Versant bDNA 3.0 assay when calibrated against the Sanquin-VQC genotype A standard (sample 1 in the reference panel). For statistical comparison of quantitative results in viral load assays it is recommended to test the samples in parallel in the same test runs until the required number of replicates per sample is available. In most cases a transformation of quantitative values is required to obtain a normal distributed dataset. After transformation one can use a paired t-test to compare mean values and to identify possible significant differences in genotype detection efficiency. For example, when a real time PCR assay is applied the Cycle to threshold (Ct) values can be used to calculate mean and standard deviation. Ideally the paired t-test should not show a significant difference. If there is a significant difference in quantitative values on the genotype standards this may be indicative for differences in genotype detection efficiency of the assay being evaluated and the bDNA 3.0 assay used to establish the 1000 cps/mL HBV reference panel.

Precautions

Warning: The HBV-DNA genotype panel members contain infectious HBV particles and are bio-hazardous. Observe the universal precautions for prevention of transmission of infectious agents when handling these materials^{7,8,9}. Although the normal human plasma used in the production of this panel was negative for infectious disease markers the reference panel members should be handled as if capable of transmitting (unknown) infectious agents. Do not pipette by mouth. Use personal protective equipment, including lab coats, gloves and safety glasses. Do not eat, drink or smoke in areas where the specimens are handled. Disinfect liquids, materials or spills with a 0.5% sodium hypochlorite solution or equivalent. Dispose of all materials and liquids used in the procedure as if they contained pathogenic agents.

Storage Instructions

It is recommended that the panel is stored at -30°C or lower to ensure highest quality. Discard any unused material after the first use. Any panel members that appear cloudy or contain visible precipitates after thawing should be discarded.

Limitations

The P0141 1000 cps/mL HBV genotype reference panel is not intended to replace the internal calibrators integral to in vitro diagnostic (IVD) test kits, but may be used as external, independent secondary or tertiary standards for the assessment of the performance of qualitative or quantitative NAT assays. A significant difference between the quantitative values assigned to the one or more members of this panel and those found by the NAT method evaluated could originate from an underestimation or overestimation of the viral load for certain genotypes by the assay under investigation. However BioQControl makes no warranty of any kind as to the suitability of this panel for the proper assessment of genotype detection efficiency of NAT systems.

References

1. Grabarczyk P, van Drimmelen H, Kopacz A, Gdowska J, Liszewski G, Piotrowski D, Górka J, Kuśmierczyk J, Candotti D, Łętowska M, Lelie N, Brojer E Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus Type 1 in blood donors. *Transfusion*. 2013 Apr 17 Epub ahead of press
2. Heermann K-K, Gerlich WH, Chudy M, Schaefer S, Thomssen RJ. Quantitative detection of hepatitis B virus DNA in two international reference preparations. *J Clin Microbiol* 1999;37:68-73
3. Chudy M, Hanschmann KM, Kress J, Nick S, Campos R, Wend U, Gerlich W, Nübling CM. First WHO International Reference Panel containing hepatitis B virus genotypes A-G for assays of the viral DNA. *J Clin Virol*. 2012;55:303-9
4. Collins ML, Zayati C, Detmer JJ, Daly B, Kolberg JA, Cha TA, Irvine BD, Tucker J, Urdea MS Preparation and characterization of DNA standards for use in quantitative branched DNA hybridization assays. *Anal Biochem*. 1995;226:120-9
5. Simmonds P. The origin and evolution of hepatitis viruses in humans. *J Gen Virol*. 2001;82:693-712
6. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. *Vox Sang*. 2001;80:63-71
7. Centers for Disease Control (CDC). Recommendations for prevention of HBV transmission in health care settings. *MMWR* 1987; 36 (supplement no. 2S).
8. Centers for Disease Control (CDC). Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. *MMWR* 1988; 37:377-388.
9. Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. *MMWR* 1989; 38(S-6): 1-36.

www.h-h-c.com



BioQControl B.V.
Visseringlaan25
2288 ER Rijswijk
The Netherlands

Tel: +31 (0)88 235 33 33
Fax: +31 (0)88 235 33 00
E-mail: info@bioqcontrol.com
Internet: www.bioqcontrol.com

KI4141
V1.0 October 2013